Thrombotic Disorders: Deep Vein Thrombosis, Pulmonary Embolism, and Thrombophilias

Thrombotic disorders represent a spectrum of conditions characterized by inappropriate blood clot formation within the vascular system. These disorders can be broadly categorized into venous thromboembolism (VTE), which includes deep vein thrombosis (DVT) and pulmonary embolism (PE), and arterial thrombosis affecting coronary, cerebral, and peripheral vessels.

Venous thromboembolism affects approximately 1-2 per 1,000 individuals annually, with significant morbidity and mortality implications. DVT typically occurs in the deep veins of the lower extremities, with the popliteal, femoral, and iliac veins being most commonly affected. PE represents the migration of thrombus from venous circulation to the pulmonary arterial system, creating a potentially life-threatening condition with case fatality rates of 10-30% if untreated.

The pathophysiology follows Virchow's triad: venous stasis, endothelial injury, and hypercoagulability. Venous stasis occurs with prolonged immobilization, mechanical compression, or anatomical abnormalities. Endothelial injury can result from trauma, surgery, central venous catheters, or inflammatory conditions. Hypercoagulability may be acquired (malignancy, hormonal therapy, pregnancy) or inherited (factor V Leiden, prothrombin gene mutation, protein C/S deficiency).

Risk factors are traditionally classified as major (recent surgery, trauma, malignancy, prolonged immobilization) and minor (age >40 years, obesity, pregnancy, oral contraceptives, hormone replacement therapy). The interplay between genetic predisposition and acquired risk factors determines individual thrombotic risk.

Clinical presentation varies significantly, with many cases being asymptomatic or presenting with nonspecific symptoms. This diagnostic challenge necessitates the use of validated clinical prediction rules and objective testing strategies to optimize patient management while avoiding overdiagnosis and unnecessary anticoagulation.

Deep vein thrombosis presents with a constellation of symptoms that can be highly variable and nonspecific. Classic presentation includes unilateral leg swelling, pain, erythema, and warmth, though many patients may be asymptomatic or present with subtle findings. Physical examination may reveal calf tenderness, palpable cord, or Homan's sign (dorsiflexion-induced calf pain), though these findings have poor diagnostic accuracy.

The Wells Score for DVT is a validated clinical prediction rule that stratifies patients into low, moderate, and high pretest probability categories. The scoring system includes:

• Active cancer (treatment within 6 months or palliative): +1 point
• Paralysis, paresis, or recent plaster immobilization: +1 point
• Recently bedridden >3 days or major surgery within 12 weeks: +1 point
• Localized tenderness along deep venous system: +1 point
• Entire leg swollen: +1 point
• Calf swelling >3 cm compared to asymptomatic leg: +1 point
• Pitting edema confined to symptomatic leg: +1 point
• Collateral superficial veins (non-varicose): +1 point
• Previously documented DVT: +1 point
• Alternative diagnosis as likely or more likely than DVT: -2 points

Scoring interpretation: ≤0 points = low probability (5% prevalence), 1-2 points = moderate probability (17% prevalence), ≥3 points = high probability (53% prevalence).

DVT Diagnostic Algorithm:

Clinical Suspicion of DVT ↓ Calculate Wells Score ↓ ├── Low Risk (≤0) → D-dimer │ ├── Negative → DVT excluded │ └── Positive → Compression ultrasound ├── Moderate Risk (1-2) → D-dimer or Compression ultrasound │ └── If D-dimer positive or US unavailable → Compression ultrasound └── High Risk (≥3) → Compression ultrasound ├── Positive → Treat for DVT ├── Negative → Consider repeat US in 1 week or venography └── If high clinical suspicion persists → Consider alternative imaging

D-dimer levels have high sensitivity (>95%) but poor specificity, particularly in hospitalized patients, elderly individuals, or those with inflammatory conditions, malignancy, or pregnancy.

Pulmonary embolism presents with diverse clinical manifestations ranging from asymptomatic to hemodynamic collapse. Common symptoms include dyspnea (80%), pleuritic chest pain (52%), cough (20%), and hemoptysis (11%). Physical findings may include tachypnea, tachycardia, hypoxemia, elevated jugular venous pressure, and in severe cases, signs of right heart strain or shock.

The Wells Score for PE stratifies patients based on clinical probability:

• Clinical signs and symptoms of DVT: +3 points
• PE is #1 diagnosis OR equally likely: +3 points
• Heart rate >100 bpm: +1.5 points
• Immobilization ≥3 days or surgery in previous 4 weeks: +1.5 points
• Previous PE or DVT: +1.5 points
• Hemoptysis: +1 point
• Malignancy (treatment within 6 months or palliative): +1 point

Scoring interpretation: ≤4 points = PE unlikely (12% prevalence), >4 points = PE likely (37% prevalence).

The PERC (Pulmonary Embolism Rule-out Criteria) can be applied to very low-risk patients (<15% pretest probability) to avoid further testing if all criteria are met: age <50 years, pulse <100 bpm, oxygen saturation ≥95%, no unilateral leg swelling, no hemoptysis, no recent surgery/trauma, no prior VTE, and no hormone use.

PE Diagnostic Algorithm:

Clinical Suspicion of PE ↓ Assess Clinical Probability (Wells Score) ↓ ├── PE Unlikely (≤4) → D-dimer │ ├── Negative → PE excluded │ └── Positive → CTPA or V/Q scan └── PE Likely (>4) → CTPA or V/Q scan ├── Positive → Treat for PE ├── Negative but high suspicion → Consider repeat imaging or alternative diagnosis └── Contraindication to CTPA → V/Q scan or ultrasound legs

CTPA (CT pulmonary angiography) is the gold standard imaging modality with sensitivity >90% for segmental and larger emboli. V/Q scanning is preferred when contrast is contraindicated or in pregnancy. Echocardiography may show right heart strain in massive PE but is not diagnostic for PE itself.

Thrombophilias are conditions that predispose individuals to thrombosis through inherited or acquired hypercoagulable states. Understanding these conditions is crucial for risk stratification, treatment decisions, and family counseling.

Inherited Thrombophilias:

Factor V Leiden is the most common inherited thrombophilia, present in 3-8% of Caucasians. This gain-of-function mutation makes factor Va resistant to protein C inactivation, increasing VTE risk 3-8 fold in heterozygotes and 50-80 fold in homozygotes.

Prothrombin G20210A mutation affects 1-3% of Caucasians, causing elevated prothrombin levels and increasing VTE risk 2-5 fold. Combined with factor V Leiden, the risk increases synergistically.

Protein C deficiency (prevalence 0.2-0.5%) and Protein S deficiency (prevalence 0.1-1%) are autosomal dominant conditions causing loss of anticoagulant function. Protein C deficiency increases VTE risk 8-10 fold, while protein S deficiency increases risk 2-11 fold.

Antithrombin deficiency is the most thrombogenic inherited thrombophilia, with VTE risk increased 10-50 fold. Type I deficiency involves decreased quantity, while Type II involves functional defects.

Acquired Thrombophilias:

Antiphospholipid syndrome (APS) is characterized by persistent antiphospholipid antibodies (lupus anticoagulant, anticardiolipin, anti-β2 glycoprotein I) associated with thrombosis and pregnancy morbidity. Laboratory criteria require positive tests on two occasions ≥12 weeks apart.

Malignancy increases VTE risk through multiple mechanisms including tissue factor expression, cytokine release, and treatment-related factors. Active cancer increases VTE risk 4-7 fold, with highest risk in pancreatic, brain, and hematologic malignancies.

Thrombophilia Testing Indications:

• VTE at age <45 years
• Recurrent VTE
• VTE at unusual sites
• Strong family history of VTE
• VTE during pregnancy or with oral contraceptives
• Recurrent pregnancy loss

Testing Considerations:

Anticoagulation remains the cornerstone of VTE treatment, with therapy selection based on patient factors, contraindications, and clinical setting. Treatment involves initial anticoagulation followed by long-term therapy, with duration determined by risk-benefit assessment.

Acute Phase Anticoagulation:

Unfractionated heparin (UFH) provides immediate anticoagulation with short half-life, making it suitable for patients requiring frequent procedures or at high bleeding risk. Dosing follows weight-based protocols targeting aPTT 1.5-2.5 times control. Monitoring requires frequent aPTT checks with dose adjustments. UFH can cause heparin-induced thrombocytopenia (HIT) in 1-3% of patients.

Low molecular weight heparin (LMWH) offers predictable pharmacokinetics with subcutaneous administration. Enoxaparin 1 mg/kg every 12 hours or 1.5 mg/kg daily are standard regimens. Monitoring anti-Xa levels is generally unnecessary except in pregnancy, renal insufficiency, or extreme body weight. LMWH has lower HIT risk than UFH.

Direct oral anticoagulants (DOACs) include factor Xa inhibitors (rivaroxaban, apixaban, edoxaban) and direct thrombin inhibitors (dabigatran). These agents offer fixed dosing without routine monitoring but require dose adjustment in renal impairment. Rivaroxaban and apixaban can be used as monotherapy, while dabigatran and edoxaban require initial parenteral anticoagulation.

Warfarin Therapy:

Warfarin requires initial parenteral anticoagulation overlap until therapeutic INR (2.0-3.0) is achieved on two consecutive measurements ≥24 hours apart. Dosing typically starts at 5-10 mg daily with frequent INR monitoring. Warfarin interacts with numerous medications and dietary vitamin K, requiring patient education and careful monitoring.

Monitoring Parameters:

Special Considerations:

Pregnancy requires LMWH or UFH, as warfarin and DOACs are teratogenic. Cancer-associated thrombosis preferentially uses LMWH for initial 3-6 months due to superior efficacy. Renal impairment necessitates dose adjustments for most agents, with severe impairment potentially requiring UFH or adjusted LMWH dosing.

Determining optimal anticoagulation duration requires balancing recurrence risk against bleeding risk, incorporating patient-specific factors and thrombosis characteristics. Duration decisions significantly impact long-term outcomes and quality of life.

Standard Duration Recommendations:

Provoked VTE (clear precipitating factor): 3 months of anticoagulation is generally sufficient for surgery-related, trauma-related, or immobilization-related thrombosis. Hormone-related VTE may warrant 3-6 months depending on whether hormones are discontinued.

Unprovoked VTE: Indefinite anticoagulation is recommended unless bleeding risk is high. After 3-6 months of initial therapy, the decision for extended therapy should be individualized.

Recurrent VTE: Indefinite anticoagulation is typically indicated regardless of provocation status, as recurrence risk remains elevated.

Cancer-associated thrombosis: Anticoagulation should continue as long as cancer remains active, typically indefinitely or until bleeding risk becomes prohibitive.

Risk Stratification Models:

The DASH score predicts bleeding risk during extended anticoagulation:

• Abnormal renal/liver function: +1 point each
• Stroke history: +1 point
• Bleeding history or predisposition: +1 point
• Labile INR (if on warfarin): +1 point
• Age >65 years: +1 point
• Drugs/alcohol concomitantly: +1 point each

Scores ≥4 indicate high bleeding risk (>5% annual major bleeding).

The HERDOO2 score identifies low-risk women who may safely discontinue anticoagulation:

• Hyperpigmentation, edema, or redness in either leg: +1 point
• D-dimer ≥250 ng/mL: +1 point
• Obesity (BMI ≥30): +1 point
• Older age (≥65): +1 point

Women with scores ≤1 have low recurrence risk (3% annually).

Extended Anticoagulation Decision Algorithm:

After 3-6 months initial therapy ↓ Assess VTE type and risk factors ↓ ├── Provoked VTE → Stop anticoagulation │ └── Monitor for recurrence ├── Unprovoked VTE → Assess bleeding vs. recurrence risk │ ├── Low bleeding risk → Continue indefinitely │ ├── High bleeding risk → Consider stopping │ └── Intermediate risk → Individualize (consider risk scores) ├── Recurrent VTE → Indefinite anticoagulation └── Cancer-associated → Continue while cancer active

Reduced-Dose Extended Therapy:

For extended anticoagulation, reduced-dose regimens may provide favorable risk-benefit profiles. Apixaban 2.5 mg twice daily and rivaroxaban 10 mg daily have demonstrated efficacy for extended treatment with potentially lower bleeding rates than full-dose therapy.

Patient Counseling Points:

• Annual recurrence risk without anticoagulation: unprovoked VTE 5-10%, cancer-associated 15-20%
• Annual major bleeding risk with anticoagulation: 1-3%
• Importance of medication adherence and monitoring
• Recognition of bleeding and thrombosis symptoms
• Lifestyle modifications and drug interactions

Thrombotic disorders present numerous management challenges requiring specialized approaches for complications, contraindications to anticoagulation, and unique clinical scenarios.

Massive Pulmonary Embolism:

Massive PE, defined by hemodynamic instability (systolic BP <90 mmHg or drop >40 mmHg), requires aggressive intervention. Thrombolytic therapy is first-line treatment in the absence of contraindications. Alteplase 100 mg IV over 2 hours or 0.6 mg/kg (max 50 mg) over 2 minutes are standard regimens.

Absolute contraindications to thrombolysis include active bleeding, recent surgery (<3 weeks), recent stroke (<3 months), and intracranial pathology. Relative contraindications require individualized risk-benefit assessment.

Embolectomy (surgical or catheter-directed) is considered when thrombolysis is contraindicated or fails. Extracorporeal membrane oxygenation (ECMO) may serve as bridge therapy in refractory cases.

Anticoagulation Contraindications:

When anticoagulation is contraindicated, IVC filter placement may prevent PE in patients with proximal DVT. Indications include active bleeding, high bleeding risk, or anticoagulation failure. Retrievable filters should be removed when anticoagulation becomes feasible, typically within 3-6 months.

Graduated compression stockings and intermittent pneumatic compression provide mechanical prophylaxis but are less effective than pharmacologic options.

Heparin-Induced Thrombocytopenia (HIT):

HIT occurs in 1-3% of heparin-exposed patients, typically 5-14 days after initiation. The 4T score assesses HIT probability:

• Thrombocytopenia degree: >50% fall (2 points), 30-50% fall (1 point)
• Timing: 5-10 days or ≤1 day with recent exposure (2 points)
• Thrombosis: New thrombosis (2 points), progressive/recurrent (1 point)
• Other causes: None apparent (2 points), possible (1 point)

Scores ≥6 indicate high HIT probability requiring immediate heparin cessation and alternative anticoagulation with argatroban or bivalirudin.

Pregnancy-Related VTE:

Pregnancy increases VTE risk 5-10 fold, with highest risk postpartum. LMWH is preferred throughout pregnancy and 6 weeks postpartum. Warfarin can be used postpartum if breastfeeding. DOACs are contraindicated in pregnancy and breastfeeding.

Dose adjustments may be necessary as pregnancy progresses due to increased renal clearance and volume of distribution. Anti-Xa monitoring may guide dosing in selected cases.

Cancer-Associated Thrombosis Treatment Algorithm:

Cancer-Associated VTE Diagnosis ↓ Assess bleeding risk and prognosis ↓ ├── Good performance status, life expectancy >6 months │ └── LMWH preferred × 3-6 months, then reassess ├── Poor prognosis or high bleeding risk │ └── Consider reduced intensity or IVC filter └── Treatment duration: Continue while cancer active

Recurrent VTE on Anticoagulation:

Breakthrough thrombosis requires evaluation of adherence, drug interactions, and adequacy of anticoagulation. Management options include increasing dose, switching agents, or adding antiplatelet therapy. Investigation for underlying causes (malignancy, antiphospholipid syndrome) should be considered.

Bleeding Complications:

Major bleeding requires immediate anticoagulation reversal when appropriate. Vitamin K reverses warfarin (onset 6-12 hours), while protamine reverses heparin. DOAC reversal agents include idarucizumab (dabigatran) and andexanet alfa (factor Xa inhibitors). Four-factor prothrombin complex concentrate may be used when specific reversal agents are unavailable.